TC Biopharm (TCBP) Stock Price, News & Analysis

Company Overview

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

Key Stats

• Today's Range: $0.50 to $1.54
• 50-Day Range: $0.50 to $7.58
• 52-Week Range: $0.50 to $523.20
• Volume: 5.33 million shs
• Average Volume: 123,869 shs
• Market Capitalization: $279,210.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $48.00
• Consensus Rating: Buy

TC Biopharm Stock Analysis - MarketRank™

TC Biopharm scored higher than 52% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

TC Biopharm has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

TC Biopharm has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

TC Biopharm has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

176.43% of the float of TC Biopharm has been sold short.

Short Interest Ratio / Days to Cover

TC Biopharm has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in TC Biopharm has recently decreased by 61.53%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TC Biopharm does not currently pay a dividend.

Dividend Growth

TC Biopharm does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

176.43% of the float of TC Biopharm has been sold short.

Short Interest Ratio / Days to Cover

TC Biopharm has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in TC Biopharm has recently decreased by 61.53%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.33

News Sentiment

TC Biopharm has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for TC Biopharm this week, compared to 1 article on an average week.

Search Interest

3 people have searched for TCBP on MarketBeat in the last 30 days.

MarketBeat Follows

Only 2 people have added TC Biopharm to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, TC Biopharm insiders have not sold or bought any company stock.

Percentage Held by Insiders

15.44% of the stock of TC Biopharm is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 16.25% of the stock of TC Biopharm is held by institutions.

TCBP Stock Analysis - Frequently Asked Questions

How have TCBP shares performed this year?

TC Biopharm's stock was trading at $10.32 at the beginning of the year. Since then, TCBP shares have decreased by 93.4% and is now trading at $0.6810.
View the best growth stocks for 2025 here.

When did TC Biopharm's stock split?

Shares of TC Biopharm reverse split on Monday, February 10th 2025. The 1-20 reverse split was announced on Wednesday, February 5th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 7th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did TC Biopharm IPO?

TC Biopharm (TCBP) raised $17 million in an initial public offering (IPO) on Friday, February 11th 2022. The company issued 4,100,000 shares at a price of $4.25 per share. EF Hutton served as the underwriter for the IPO.

How do I buy shares of TC Biopharm?

Shares of TCBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of TC Biopharm own?

Based on aggregate information from My MarketBeat watchlists, some other companies that TC Biopharm investors own include Johnson & Johnson (JNJ), Procter & Gamble (PG), Taiwan Semiconductor Manufacturing (TSM), Exxon Mobil (XOM), International Business Machines (IBM), NextEra Energy (NEE) and Union Pacific (UNP).

Company Calendar

• Today: 3/28/2025
• Next Earnings (Estimated): 4/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TCBP
• CIK: 1872812
• Web: www.tcbiopharm.com
• Phone: 44-14-1433-7557
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $48.00
• High Stock Price Target: $48.00
• Low Stock Price Target: $48.00
• Potential Upside/Downside: +6,948.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.67
• Current Ratio: 1.12
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $4.76 million
• Price / Sales: 0.06
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $519.58 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 410,000
• Free Float: 28,000
• Market Cap: $279,210.00
• Optionable: Not Optionable
• Beta: 0.01